Skip to content
  • info@aberabio.com
cropped-Abera.png
  • About Abera
    • About us
    • Management
    • Board of directors
    • Advisory board
    • Career
  • Technology
  • Projects
  • News
  • Investors
    • The Share
    • Financial Reports
    • External financial analysis
    • Presentations
    • Annual General Meeting 2025
    • Shareholders
    • Corporate Governance
    • Investor Relation Contact
  • Contact
    • Contact us
    • Partner & Licensing
Menu
  • About Abera
    • About us
    • Management
    • Board of directors
    • Advisory board
    • Career
  • Technology
  • Projects
  • News
  • Investors
    • The Share
    • Financial Reports
    • External financial analysis
    • Presentations
    • Annual General Meeting 2025
    • Shareholders
    • Corporate Governance
    • Investor Relation Contact
  • Contact
    • Contact us
    • Partner & Licensing

Abera publish Annual Report 2022

  • May 17, 2023
  • 6:51 am

Abera Bioscience AB today publish the annual report for 2022 in Swedish, see below.

Read it here: Abera Bioscience Årsredovisning 2022

PrevPreviousNotice of annual meeting for Abera Bioscience AB
NextKommuniké från årsstämma i Abera Bioscience ABNext
back to home page
back to news & events

contact us

Get in contact with us via the contact form or email: info@aberabio.com

  • Abera Bioscience AB
    Virdings allé 32
    754 50 Uppsala
  • info@aberabio.com
cropped-Abera.png

Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.

  • Abera Bioscience AB
    Virdings allé 32
    754 50 Uppsala
  • info@aberabio.com
  • Home
  • About Abera
  • Technology
  • Projects
  • News
  • Investors
  • Contact
  • Home
  • About Abera
  • Technology
  • Projects
  • News
  • Investors
  • Contact

NEws

Abera Bioscience carries out directed issue of units to finance clinical Phase I study of pneumococcal vaccine candidate Ab-01.12

Read more

Artikel: Nästa pandemi – varför vaccinet måste vara snabbare än viruset

Read more

Communiqué from the Annual General Meeting of Abera Bioscience AB

Read more
  • © 2024 Abera Bioscience AB.​